

**WHAT IS CLAIMED:**

5 ~~39~~. A method of treating a subject having systemic lupus erythematosus comprising the extracorporeal removal of lupus antibodies from the subject's plasma and returning the plasma to the subject.

~~40~~. The method of claim 39, wherein the removal of lupus antibodies is performed by column chromatography on a column adsorbed with at least one type of peptide.

10 ~~3~~ ~~41~~. The method of claim 40, wherein the peptide is selected from the group consisting of SEQ. ID. NO. 1, SEQ. ID. NO. 2, SEQ. ID. NO. 3, SEQ. ID. NO. 4, SEQ. ID. NO. 5, SEQ. ID. NO. 6, SEQ. ID. NO. 7, SEQ. ID. NO. 8, SEQ. ID. NO. 9, SEQ. ID. NO. 10, SEQ. ID. NO. 11, SEQ. ID. NO. 12, SEQ. ID. NO. 13, SEQ. ID. NO. 14, SEQ. ID. NO. 15, SEQ. ID. NO. 16, SEQ. ID. NO. 17, SEQ. ID. NO. 18, SEQ. ID. NO. 19, SEQ. ID. NO. 20, SEQ. ID. NO. 21, and SEQ. ID. NO. 22.

~~42~~. The method of claim 40, wherein the column is adsorbed with two or more types of peptides.

20 ~~43~~. The method of claim 41, wherein the peptides are selected from the group consisting of SEQ. ID. NO. 10, SEQ. ID. NO. 19, SEQ. ID. NO. 20, SEQ. ID. NO. 21.

~~44~~. The method of claim 41, wherein the peptide has SEQ. ID. NO. 1.

25 ~~7~~ ~~45~~. The method of claim 41, wherein the peptide has SEQ. ID. NO. 10.

~~46~~. The method of claim 41, wherein the column is a N-hydroxysuccinimide (NHS)-activated Sepharose™ High Performance Column.